Trend of SARS-Cov-2-Specific IgG Antibody Titers Among COVID-19 Pneumonia Patients: A Nine-Month Follow-Up DOI Open Access
Manzoor Ahmad,

Mohammad Muttahir Uddin,

Abdul Ahad Wani

et al.

Cureus, Journal Year: 2023, Volume and Issue: unknown

Published: June 23, 2023

Introduction Understanding the dynamics of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin G (IgG) spike antibody titers after natural infection is important for understanding immunological memory. This longitudinal study was conducted to assess trend in serum SARS-CoV-2 IgG a cohort recovered cases up nine months SARS infection. Materials and methods We examined neutralizing response (IgG spike) samples from 86 quantitative polymerase chain reaction (qPCR)-confirmed infection, comprising having minor COVID-19 pneumonia severity, which determined by CT severity scores. Patients were enrolled August/September 2020 have been processed at one, three, six, months. scores rated between 1-25 titers≥ 1.4 considered positive. Results The mean anti-SARS-CoV-2-specific one month, three months, six 22.02 ± 18.36, 14.62 12.61, 8.93 8.10, 3.86 5.70, respectively. difference statistically significant. seropositivity rates (titer ≥1.4 IU) 93.02%, 82.56%, 76.74%, 58.14% Cases with severe showed significantly higher levels all follow-up visits.

Language: Английский

Humoral response after a fourth dose of SARS-CoV-2 vaccine in immunocompromised patients. Results of a systematic review DOI Creative Commons
Silvia Martinelli, Domenico Pascucci, Patrizia Laurenti

et al.

Frontiers in Public Health, Journal Year: 2023, Volume and Issue: 11

Published: March 23, 2023

The fourth dose the COVID-19 vaccine was first proposed to immunocompromised patients. aim of article is systematically review literature and report humoral response outcomes after administration in people with impaired immune system.

Language: Английский

Citations

22
Humoral and T-cell response 12 months after the first BNT162b2 vaccination in solid organ transplant recipients and controls: Kinetics, associated factors, and role of SARS-CoV-2 infection DOI Creative Commons
Omid Rezahosseini, Sebastian Rask Hamm, Line Dam Heftdal

et al.

Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 13

Published: Jan. 13, 2023

Introduction We investigated humoral and T-cell responses within 12 months after first BNT162b2 vaccine in solid organ transplant (SOT) recipients controls who had received at least three doses. Furthermore, we compared the immune response participants with without previous SARS-CoV-2 infection. Methods included adult liver, lung, kidney recipients, were selected from a parallel cohort of healthcare workers. Results At 12th-month, IgG geometric mean concentrations (GMCs) (P<0.001), IgA GMCs (P=0.003), median IFN-γ (P<0.001) lower SOT than controls. However, infection, neutralizing index was 99%, IgG, comparable. After adjustment, female-sex (aOR: 3.6, P<0.009), 7.0, P= 0.008) or lung transplantation 7.5, 0.014), use mycophenolate 5.2, P=0.03) associated low non response. Age (OR:1.4, P=0.038), time to (OR: 0.45, P<0.035), infection 0.14, P<0.001), Diabetes (OR:2.4, P=0.044) Conclusion In conclusion, inferior but comparable

Language: Английский

Citations

11
Vaccine Effectiveness Against the SARS-CoV-2 B.1.1.529 Omicron Variant in Solid Organ and Islet Transplant Recipients in England: A National Retrospective Cohort Study DOI Creative Commons
Chris Callaghan, Rebecca Curtis,

Lisa Mumford

et al.

Transplantation, Journal Year: 2023, Volume and Issue: 107(5), P. 1124 - 1135

Published: Jan. 25, 2023

The effectiveness of vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.1.529 Omicron variant in immunosuppressed solid organ and islet transplant (SOT) recipients is unclear.National registries England were linked to identify SARS-CoV-2 positive tests, noninjury hospitalization within 14 d, deaths 28 d between December 7, 2020, March 31, 2022 adult SOT recipients. Incidence rate ratios (IRRs) for infection, or death, adjusted recipient demographics calendar month Omicron-dominant period (December 20, 2021, 2022). Mortality risk following infection was dominant using a Cox proportional-hazards model entire time period.During period, IRRs (95% confidence intervals) higher those receiving 2, 3, 4 vaccine doses than unvaccinated patients (1.25 [1.08-1.45], 1.46 [1.28-1.67], 1.79 [1.54-2.06], respectively). However, death during this lower 3 (0.62 [0.45-0.86] 0.39 [0.26-0.58], Risk-adjusted analyses after 2022, found hazard 0.67 (0.46-0.98), 0.46 (0.30-0.69), 0.18 (0.09-0.35) with doses, respectively, when compared group.In recipients, vaccination associated incremental, dose-dependent protection including variant.

Language: Английский

Citations

11
Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccines DOI Creative Commons
Moe H. Kyaw, Júlia Spinardi, Ling Zhang

et al.

Human Vaccines & Immunotherapeutics, Journal Year: 2023, Volume and Issue: 19(1)

Published: Jan. 2, 2023

Introduction of primary COVID-19 vaccination has helped reduce severe disease and death caused by SARS-CoV-2 infection. Understanding the protection conferred heterologous booster regimens informs alternative strategies that enable programmatic resilience can catalyze vaccine confidence coverage. Inactivated vaccines are among most widely used worldwide. This review synthesizes available evidence identified as May 26, 2022, on safety, immunogenicity, effectiveness a BNT162b2 (Pfizer-BioNTech) mRNA dose after an inactivated series, to help protect against COVID-19. Evidence showed BNT16b2 enhances immunogenicity improves COVID-19, no new safety concerns were with series combinations.

Language: Английский

Citations

11
Results of the Stop the Spread Ottawa (SSO) cohort study: a Canadian urban-based prospective evaluation of antibody responses and neutralisation efficiency to SARS-CoV-2 infection and vaccination DOI Creative Commons
Alexa Keeshan,

Yannick Galipeau,

Aliisa Heiskanen

et al.

BMJ Open, Journal Year: 2023, Volume and Issue: 13(10), P. e077714 - e077714

Published: Oct. 1, 2023

Predictors of COVID-19 vaccine immunogenicity and the influence prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection require elucidation.Stop Spread Ottawa is a prospective cohort individuals at-risk for or who have been infected with SARS-CoV-2, initially enrolled 10 months beginning October 2020. This was enriched public-facing workers. analysis focuses on safety initial two doses vaccine.Post-vaccination data blood specimens were available 930 participants. 22.8% SARS-CoV2 to first dose. Cohort characteristics include: median age 44 (IQR: 22-56), 66.6% women, 89.0% white, 83.2% employed. 38.1% reported more comorbidities 30.8% immune compromising condition(s). Over 95% had detectable IgG levels against spike receptor binding domain (RBD) 3 post second By multivariable analysis, increasing high-level compromise predicted diminishing RBD titres at month higher immediately vaccination in those SARS-CoV-2 6 wider time intervals between dose 1 2. neutralisation generally similar by sex, weight whether receiving homogeneous heterogeneous combinations vaccines. Common symptoms included fatigue (64.7%), injection site pain (47.5%), headache (27.2%), fever/chills (26.2%) body aches (25.3%). These subsequent doses.The are safe, well-tolerated highly immunogenic across broad spectrum recipients including working public facing environments.

Language: Английский

Citations

7
Evidence of the Efficacy and the Effectiveness of First Generation COVID-19 Vaccines in Clinical Trials and Real-world Studies DOI Creative Commons
Jingxin Li,

Zhuopei Li,

Yawen Zhu

et al.

Zoonoses, Journal Year: 2022, Volume and Issue: 2(1)

Published: Jan. 1, 2022

More than 300 COVID-19 vaccine candidates have been developed or are currently in development. vaccines on the World Health Organization’s Emergency Use Listing and other products conditionally approved by national regulatory authorities already large-scale use, thus preventing severe illness death inducing herd immunity at population level SARS-CoV-2 pandemic. In this review, we systemically assess efficacy effectiveness of clinical trials real-world studies, various populations, including healthy adults, children, older people, pregnant people with cancer, receiving long-term hemodialysis solid organ transplantation. addition, review available evidence regarding immunization strategies a history infection, enhanced conferred booster immunizations. We also discuss knowledge gaps persistence spectrum protection vaccines.

Language: Английский

Citations

5
Impact of Anti-TNFα Treatment on the Humoral Response to the BNT162b2 mRNA COVID-19 Vaccine in Pediatric Inflammatory Bowel Disease Patients DOI Creative Commons
Kosuke Kashiwagi, Keisuke Jimbo, Mitsuyoshi Suzuki

et al.

Vaccines, Journal Year: 2022, Volume and Issue: 10(10), P. 1618 - 1618

Published: Sept. 27, 2022

The efficacy of the COVID-19 mRNA vaccine, including third vaccination in pediatric inflammatory bowel disease (PIBD) patients is not fully understood. This study aimed to evaluate humoral immunogenicity BNT162b2 vaccine and changes durability until 20–28 weeks after initial series PIBD on immunosuppressive drugs. safety booster effect were also evaluated. A single-center, prospective cohort was conducted, 63 participants (anti-TNFα: 11; non-anti-TNFα: 31; 5-ASA: 21), with a mean age 15.2 (range 9.6–17.9) years, enrolled. All seroconverted, no serious short-term AEs. anti-TNFα had significantly lower antibody titers than those other medications at all measurement points. Furthermore, waned over time 3–9 two-vaccine series. In 10 5; non-anti-TNFα 5), led concentrations higher same point second vaccination. need remain vigilant about even two vaccinations, may be considered.

Language: Английский

Citations

3
Immunogenicity and Determinants of Antibody Response to the BNT162b2 mRNA Vaccine: A Longitudinal Study in a Cohort of People Living with HIV DOI Creative Commons
Tatjana Baldovin,

Davide Leoni,

Ruggero Geppini

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 12(10), P. 1172 - 1172

Published: Oct. 16, 2024

The COVID-19 pandemic posed significant challenges worldwide, with SARS-CoV-2 vaccines critical in reducing morbidity and mortality. This study evaluates the immunogenicity antibody persistence of BNT162b2 vaccine people living HIV (PLWH).

Language: Английский

Citations

0
Impact of Immunosuppressants and Vaccination on COVID-19 Outcomes in Autoimmune Patients and Solid Organ Transplant Recipients: A Nationwide Propensity Score-Matched Study DOI Creative Commons
MinDong Sung, Young Sam Kim, Chang Jin Cho

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 12(10), P. 1190 - 1190

Published: Oct. 18, 2024

This study investigates the impact of varying degrees immunosuppression on clinical outcomes immunocompromised individuals, particularly those with autoimmune diseases or post-solid organ transplant statuses, in context COVID-19. By focusing these highly vulnerable populations, underscores significant health inequalities faced by patients, who experience disproportionately worse comparison to general population.

Language: Английский

Citations

0
Impact of Immune Abnormalities on COVID-19 Vaccine Effectiveness in Infected Patients DOI Open Access
Yunhui Chen,

Wanxia Luo,

Qiyu Huang

et al.

Cureus, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 21, 2024

Objective To assess the protective effect of COVID-19 vaccines in patients with varying immune states by analyzing lactate dehydrogenase (LDH), C-reactive protein (CRP), and D-dimer (D-Di) levels COVID-19-infected individuals under different vaccination scenarios statuses. Methods This is a single-center retrospective study involving 338 SARS-CoV-2-infected treated at tertiary medical center Foshan, China, between November 2022 January 2023. The primary outcome was vaccine's on LDH, CRP, D-Di levels. Results Vaccinated had shorter hospital stays less severe lung involvement (P < 0.05), particularly immunocompromised individuals. In patients, LDH CRP were elevated, but vaccine group, fewer developed abnormally high D-Di, coagulation-related complications. Vaccination reduced immunocompetent lowered regardless status. addition, people who are both vaccinated have higher risk developing microthrombosis. Conclusions generally improves levels, supporting efforts. However, subset exhibited upon admission, suggesting complex interplay vaccination, status, finding emphasizes need for further investigation into role function disease severity response.

Language: Английский

Citations

0